Sign in

You're signed outSign in or to get full access.

Rabib Chaudhury

Research Analyst at Leerink Partners

Rabib Chaudhury, Ph.D., is an Equity Research Associate at Leerink Partners, specializing in immuno-oncology within the biotechnology sector. He collaborates with senior analysts such as Daina M. Graybosch, Ph.D., and Jeffrey La Rosa on coverage of emerging oncology companies, though specific company names and performance metrics like success rates or rankings on platforms such as TipRanks are not detailed in available sources. Chaudhury is based in New York, NY, with his professional timeline and prior firm experience undisclosed in public records, and holds a Ph.D. as his primary credential, with no FINRA registrations or securities licenses specified.

Rabib Chaudhury's questions to COMPUGEN (CGEN) leadership

Question · Q4 2025

Rabib Chaudhury asked about the expected details for the Q1 2027 COM-701 update and the timeline and requirements for a potential path to registration for the drug.

Answer

Dr. Michelle Mahler (Chief Medical Officer) explained that the Q1 2027 update will involve data maturation from the adaptive trial design, with registration requirements depending on the totality of the data. David Silberman (CFO) added that positive data could fast-forward monotherapy, open paths for combination strategies, and other options.

Ask follow-up questions

Fintool

Fintool can predict COMPUGEN logo CGEN's earnings beat/miss a week before the call

Question · Q4 2025

Rabib Chaudhury asked about expectations for the Q1 2027 update on COM-701, specifically what data will be presented, and inquired about the timeline and requirements for a potential path to registration for the drug.

Answer

Dr. Michelle Mahler (Chief Medical Officer) stated that data maturation is anticipated in Q1 2027 and the path to registration will depend on the totality of the data, with subsequent plans still under discussion. Eran Ophir (President and CEO) added that positive data could fast-forward monotherapy, open paths for combination strategies, and enable broader development.

Ask follow-up questions

Fintool

Fintool can write a report on COMPUGEN logo CGEN's next earnings in your company's style and formatting